BASEL — Novartis is scheduled to release quarterly results on Tuesday, as investors prepare to assess the company's trajectory ahead of critical clinical milestones. The Basel, Switzerland-based pharmaceutical giant is under investor focus as it seeks to validate its valuation with upcoming data from its experimental drug pipeline.

Three major drug trial readouts are due in the second half of 2026, representing a pivotal period for the company's growth strategy. These trials involve pelacarsen, an experimental drug for cardiovascular disease; remibrutinib, an experimental drug for multiple sclerosis; and del-desiran, an experimental drug for a genetic disorder.

Analysts estimate the three drugs have a combined peak annual sales potential of more than $10 billion. This revenue projection reflects the financial stakes attached to the clinical outcomes expected later this year. Investors and market observers are closely monitoring these developments as potential drivers of future earnings.

Novartis currently holds a forward earnings valuation multiple of approximately 16 times. This metric places the company at a premium that requires consistent delivery on its growth promises to maintain market confidence. The stock has performed strongly in recent periods, with shares rising approximately 25% over the past 12 months.

Year-to-date performance has also been positive, with Novartis shares rising 11% in 2026 so far. This gain reflects ongoing investor interest, though the sustainability of this trajectory depends heavily on the success of the upcoming trials. The company's ability to meet market expectations will be tested as the readout dates approach.

Goldman Sachs analyst James Quigley stated that Novartis needs at least two of the three upcoming trials to succeed. He emphasized the sensitivity of the company's valuation to these binary outcomes. "If two of those fail, that 16-times multiple looks very, very vulnerable," Quigley said.

The pressure on the pipeline comes as the company faces impending patent expiries for its blockbuster drugs Cosentyx and Kisqali. Cosentyx is used to treat psoriasis and arthritis, while Kisqali is a therapy for breast cancer. These patents are expected to expire around the turn of the decade, potentially opening the door to generic competition.

In the nearer term, sales of the heart drug Entresto are expected to drop by $4 billion in 2026. Entresto is facing competition from generic drugs, which is eroding its market share. This decline contributes to the urgency for Novartis to bring new therapies to market to offset revenue losses from older products.

The HORIZON study, which is the trial for pelacarsen, is testing whether lowering lipoprotein(a), or Lp(a), reduces the risk of heart attacks or strokes. This cardiovascular endpoint is a key area of unmet medical need. The trial's results will determine the drug's potential impact on patient care and its commercial viability.

UBS analysts expect pelacarsen could reach statistical significance at around a 12% relative risk reduction. However, clinicians may want to see a 15% or greater relative risk reduction to view the pelacarsen result as clearly meaningful. This gap between statistical success and clinical perception adds another layer of complexity to the interpretation of the trial data.

Jefferies analyst Michael Leuchten commented on the valuation dynamics surrounding the trials. "At 16 times, you do need those growth levers to come through," Leuchten said. He suggested that the timing of the releases could influence market reaction. "It's more about the momentum in the second half, and then you might as well tuck in the slightly riskier pipeline readouts that are around the corner," Leuchten added.

Whitefriars, a London-based investor in Novartis, showed the volatility inherent in pharmaceutical research and development. Fund manager Ketan Patel noted the market's tendency to react sharply to clinical data. "Markets can be unforgiving in R&D...with even a small shortfall in clinical trials being punished heavily, whilst knockout results are treated with relief," Patel said.

Vas Narasimhan is the Chief Executive of Novartis and has led the company for eight years. His leadership will be closely watched as the company navigates this critical phase of pipeline development. Management's communication strategy and operational execution will be central to maintaining investor confidence during this period.

The outcome of these trials will determine whether Novartis can offset billions in lost revenue from aging products like Entresto and patent-exposed drugs such as Cosentyx and Kisqali. With a combined sales potential exceeding $10 billion, the success of pelacarsen, remibrutinib, and del-desiran is essential for sustaining the company's 16-times earnings multiple. Failure to meet clinical expectations could trigger a significant revaluation of the stock, as analysts have warned that missing on two of the three trials would leave the current price structure vulnerable. The results also carry implications for patient treatment options in cardiovascular disease, multiple sclerosis, and genetic disorders, areas where new therapies are urgently needed.